國立虎尾科技大學 |

Clinical pharmacokinetic and pharmacodynamic drug interactions associated with antimalarials

Record Type:	Language materials, printed : Monograph/item
Title/Author:	Clinical pharmacokinetic and pharmacodynamic drug interactions associated with antimalarials/ by Tony K.L. Kiang, Kyle John Wilby, Mary H.H. Ensom.
Author:	Kiang, Tony K.L.
other author:	Wilby, Kyle John.
Published:	Cham :Springer International Publishing : : 2015.,
Description:	vii, 146 p. :ill., digital ; : 24 cm.;
Contained By:	Springer eBooks
Subject:	Antimalarials - Pharmacokinetics. -
Online resource:	http://dx.doi.org/10.1007/978-3-319-10527-7
ISBN:	9783319105277 (electronic bk.)

Clinical pharmacokinetic and pharmacodynamic drug interactions associated with antimalarials
Kiang, Tony K.L.

Clinical pharmacokinetic and pharmacodynamic drug interactions associated with antimalarials[electronic resource] /by Tony K.L. Kiang, Kyle John Wilby, Mary H.H. Ensom. - Cham :Springer International Publishing :2015. - vii, 146 p. :ill., digital ;24 cm.

Introduction -- Pharmacology of Recommended Antimalarial Agents -- Drug Interaction Potential of Antimalarial Drugs Based on Known Metabolic Properties of Antimalarials -- Pharmacokinetic Drug Interactions Affecting Antimalarials -- Effects of Antimalarials on the Pharmacokinetics of Co-Administered Drugs -- Effects of Antimalarials on the Pharmacokinetics of Co-Administered Antimalarials -- Pharmacodynamic Interactions: Clinical Evidence for Combination Therapy, In Vitro Interactions, and In Vivo Interactions -- Limitations, Future Directions, and Conclusions.

This comprehensive review provides a systematic, unbiased analysis, critique and summary of the available literature and generates novel clinical decision-making algorithms which can aid clinicians and scientists in practice management and research development. Potential mechanisms for the identified drug interactions are deduced from available preclinical and in vitro data which are interpreted in the context of the in vivo findings. Current limitations and gaps in the literature are summarized, and potential future research directions / experimentations are also suggested. In addition to the main objective to review the available clinical pharmacokinetic and pharmacodynamic drug interactions associated with WHO-recommended antimalarial drugs on the market today (i.e. chloroquine, amodiaquine, sulfadoxine, pyrimethamine, mefloquine, artemisinin, artemether, artesunate, dihydroartemisinin, artemotil, lumefantrine, primaquine, atovaquone, proguanil, piperaquine and quinine), this book also provides succinct chapter summaries on the epidemiology of malaria infection, diagnosis and therapeutics, in vivo pharmacology and chemistry, preclinical pharmacology, in vitro pharmacodynamics, in vitro reaction phenotyping, and in vitro drug-drug interaction data associated with the identified antimalarial drugs.

ISBN: 9783319105277 (electronic bk.)

Standard No.: 10.1007/978-3-319-10527-7doiSubjects--Topical Terms:

1064649
Antimalarials
--Pharmacokinetics.

LC Class. No.: RC159.A5

Dewey Class. No.: 616.9362061

Clinical pharmacokinetic and pharmacodynamic drug interactions associated with antimalarials
LDR:02881nam a2200313 a 4500 001 835397
003 DE-He213
005 20150724100116.0
006 m d
007 cr nn 008maaau
008 160421s2015 gw s 0 eng d
020 $a 9783319105277 (electronic bk.)
020 $a 9783319105260 (paper)
024 7 $a 10.1007/978-3-319-10527-7 $2 doi
035 $a 978-3-319-10527-7
040 $a GP $c GP
041 0 $a eng
050 4 $a RC159.A5
072 7 $a MMRT $2 bicssc
072 7 $a MED097000 $2 bisacsh
082 0 4 $a 616.9362061 $2 23
090 $a RC159.A5 $b K46 2015
100 1 $a Kiang, Tony K.L. $3 1064646
245 1 0 $a Clinical pharmacokinetic and pharmacodynamic drug interactions associated with antimalarials $h [electronic resource] / $c by Tony K.L. Kiang, Kyle John Wilby, Mary H.H. Ensom.
260 $a Cham : $b Springer International Publishing : $b Imprint: Adis, $c 2015.
300 $a vii, 146 p. : $b ill., digital ; $c 24 cm.
505 0 $a Introduction -- Pharmacology of Recommended Antimalarial Agents -- Drug Interaction Potential of Antimalarial Drugs Based on Known Metabolic Properties of Antimalarials -- Pharmacokinetic Drug Interactions Affecting Antimalarials -- Effects of Antimalarials on the Pharmacokinetics of Co-Administered Drugs -- Effects of Antimalarials on the Pharmacokinetics of Co-Administered Antimalarials -- Pharmacodynamic Interactions: Clinical Evidence for Combination Therapy, In Vitro Interactions, and In Vivo Interactions -- Limitations, Future Directions, and Conclusions.
520 $a This comprehensive review provides a systematic, unbiased analysis, critique and summary of the available literature and generates novel clinical decision-making algorithms which can aid clinicians and scientists in practice management and research development. Potential mechanisms for the identified drug interactions are deduced from available preclinical and in vitro data which are interpreted in the context of the in vivo findings. Current limitations and gaps in the literature are summarized, and potential future research directions / experimentations are also suggested. In addition to the main objective to review the available clinical pharmacokinetic and pharmacodynamic drug interactions associated with WHO-recommended antimalarial drugs on the market today (i.e. chloroquine, amodiaquine, sulfadoxine, pyrimethamine, mefloquine, artemisinin, artemether, artesunate, dihydroartemisinin, artemotil, lumefantrine, primaquine, atovaquone, proguanil, piperaquine and quinine), this book also provides succinct chapter summaries on the epidemiology of malaria infection, diagnosis and therapeutics, in vivo pharmacology and chemistry, preclinical pharmacology, in vitro pharmacodynamics, in vitro reaction phenotyping, and in vitro drug-drug interaction data associated with the identified antimalarial drugs.
650 0 $a Antimalarials $x Pharmacokinetics. $3 1064649
650 0 $a Antimalarials $x Receptors $x Effect of drugs on. $3 1064650
650 1 4 $a Medicine & Public Health. $3 593949
650 2 4 $a Tropical Medicine. $3 668883
650 2 4 $a Health Promotion and Disease Prevention. $3 593964
650 2 4 $a Drug Safety and Pharmacovigilance. $3 1064651
700 1 $a Wilby, Kyle John. $3 1064647
700 1 $a Ensom, Mary H.H. $3 1064648
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer eBooks
856 4 0 $u http://dx.doi.org/10.1007/978-3-319-10527-7
950 $a Medicine (Springer-11650)